Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047506 | 0.99 | ANPEP (0.33) | ANPEPDPP4ALDH1A1ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL739370 | 0.87 | DPP4 (0.33) | ANPEPDPP4ALDH1A1ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL1727633 | 0.86 | DPP4 (0.32) | ANPEPDPP4ALDH1A1ALOX15TSHR | |
| SCHEMBL819459 | 0.86 | DPP4 (0.33) | ANPEPDPP4ALDH1A1ALOX15TSHR | |
| SCHEMBL12503773 | 0.84 | DPP4 (0.33) | ANPEPDPP4ALDH1A1ALOX15TSHR | |
| SCHEMBL2149891 | 0.84 | DPP4 (0.33) | ANPEPDPP4ALDH1A1ALOX15TSHR | |
| SCHEMBL16465929 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL23326872 | 0.82 | ANPEP (0.36) | ANPEPDPP4ALDH1A1ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL442699 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1609624 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2574187-B1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | AMYRIS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-17 | — | — | US | disclosed |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-01-07 | — | — | US | disclosed |
| US-9072729-B2 | Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-07 | — | — | US | disclosed |
| EP-2803356-A1 | Method for treating neurological disorders with imidazolium and imidazolinium compounds | Agency for Science, Technology and Research (SG) | 2014-11-19 | — | — | EP | disclosed |
| US-8586814-B2 | Squalane and isosqualane compositions and methods for preparing the same | Amyris, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2574187-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | Amyris Biotechnologies, Inc. (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20130053566-A1 | CATIONIC PALLADIUM COMPLEXES COMPRISING DIAMINO CARBENE LIGANDS AND THEIR USE IN CATALYSIS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2013-02-28 | — | — | US | disclosed |
| WO-2011146837-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | Amyris, Inc. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110287988-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | EUAGORE, LLC | 2011-11-24 | — | — | US | disclosed |
| WO-2011127579-A1 | CATIONIC PALLADIUM COMPLEXES COMPRISING DIAMINO CARBENE LIGANDS AND THEIR USE IN CATALYSIS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2011-10-20 | — | — | WO | disclosed |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-07-21 | — | — | US | disclosed |
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028513-A1 | METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | SMN1; SMN2, INA, NLN | ANPEP 1351/4885DPP4 782/4885ALDH1A1 2486/4885 |
| US-20110287988-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | SQLE, FDFT1, COASY | ANPEP 1900/4885DPP4 3630/4885ALDH1A1 155/4885 |
| US-20110178040-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | ANPEP 2080/4885DPP4 1055/4885ALDH1A1 1225/4885 |
| US-20130053566-A1 | CATIONIC PALLADIUM COMPLEXES COMPRISING DIAMINO CARBENE LIGANDS AND THEIR USE IN CATALYSIS | MLX, LBR, LRRK2 | ANPEP 2810/4885DPP4 1917/4885ALDH1A1 2938/4885 |
| US-20160331727-A9 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | ANPEP 2080/4885DPP4 1055/4885ALDH1A1 1225/4885 |
| US-20160000757-A1 | METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS | MMP1, MYLK, MMP8 | ANPEP 2080/4885DPP4 1055/4885ALDH1A1 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.